Important note: Information in this article was accurate in 2006. The state of the art may have changed since the publication date.
Associated Press - December 22, 2006
Under the agreement, Valeant will retain an option to reacquire rights to commercialize the HIV program outside the U.S. after Ardea completes its main clinical trials. Ardea is required to pay Valeant for achieving certain development milestones and royalties if it commercializes either the cancer or HIV compounds.
Valeant Chief Executive Timothy Tyson said the sale is part of the company's reorganization plan.
"The agreement will further the development of important programs for HIV and other therapies while allowing us to retain an interest in the commercial rights to our HIV compounds," said Timothy Tyson.
Shares of Valeant added 6 cents to $17.55 in morning trading on the New York Stock Exchange.
061222
AP061250
Copyright © 2006 - Associated Press. Reproduction of this article (other than one copy for personal reference) must be cleared through the AP Permissions Desk.
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, National Library of Medicine, and donations from users like you.
Always watch for outdated information. This article first appeared in 2006. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2006. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .